Research and Markets: Hyperinsulinemia - Pipeline Review, H2 2012 Covers Key Discontinued Pipeline Projects

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pqwvr8/hyperinsulinemia) has announced the addition of Global Markets Direct's new report "Hyperinsulinemia - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Hyperinsulinemia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hyperinsulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperinsulinemia. Hyperinsulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Hyperinsulinemia.

- A review of the Hyperinsulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Hyperinsulinemia pipeline on the basis of route of administration and molecule type.

- Latest news and deals relating to the products.

Companies Mentioned:

Biodel Inc.

Amunix, Inc.

For more information visit http://www.researchandmarkets.com/research/pqwvr8/hyperinsulinemia

Source: Global Markets Direct